TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus.  In December 2017, we licensed the rights to develop and commercialize TTP273 in China and certain Pacific Rim territories to Huadong Medicine.

GLP-1 is a member of the incretin family of neuroendocrine peptide hormones secreted from L-cells of the intestine in response to food ingestion. GLP-1 has multiple metabolic effects that are attractive for an anti-diabetic agent, which have been validated by existing injectable peptide GLP-1R agonists.

TTP273 has completed a 3 month phase 2 study in patients with type 2 diabetes where it demonstrated a statistically significant reduction in HbA1c. TTP273 was well-tolerated, with negligible incidences of nausea and vomiting across all arms of the study. Trends towards weight loss were also observed.

Presentations and Posters

Links to the following publications and presentations, which are located on outside websites, are provided for informational purposes only and do not constitute the opinions or views of vTv Therapeutics